| Literature DB >> 31635309 |
Qiongyao Hu1, Shaohua Xu2, Cheng Ye3, Jingyi Jia4, Lingling Zhou5, Guangfu Hu6.
Abstract
Epidermal growth factor (EGF) is a member of the EGF-like ligands family, which plays a vital role in cell proliferation, differentiation, and folliculogenesis through binding with EGF receptors, including ErbB1 (EGFR/HER1), ErbB2 (HER2), ErbB3 (HER3), and ErbB4 (HER4). In mammals, many functional roles of EGF have been reported in the ovaries and breasts. However, little is known about the functions of EGF in the pituitary, especially in teleost. In this study, using grass carp pituitary cells as the model, we try to examine the direct pituitary actions of EGF in teleost. Firstly, transcriptomic analysis showed that 599 different expressed genes (DEGs) between the control and EGF-treatment group were mainly involved in cell proliferation, cell migration, signal transduction, and transcriptional regulation. Then, we further confirmed that EGF could significantly induce UTS1, EGR1, and MMP13 mRNA expression in a time-and dose-dependent manner. The stimulatory actions of EGF on UTS1 and EGR1 mRNA expression were mediated by the MEK1/2/ERK1/2 and PI3K/AKT/mTOR pathways coupled with both ErbB1 and ErbB2 in grass carp pituitary cells. The receptor specificity and signal transductions for the corresponding responses on MMP13 mRNA expression were also similar, except that the ErbB2 and PI3K/AKT/mTOR pathway were not involved. As we know, MMP13 could release EGF from HB-EGF. Interestingly, our data also showed that the MMPs inhibitor BB94 could suppress EGF-induced UTS1 and EGR1 mRNA expression. These results, taken together, suggest that the stimulatory actions of EGF on UTS1 and EGR1 mRNA expression could be enhanced by EGF-induced MMP13 expression in the pituitary.Entities:
Keywords: ErbB; grass carp; pharmacological test; pituitary cells; signal transduction
Mesh:
Substances:
Year: 2019 PMID: 31635309 PMCID: PMC6829292 DOI: 10.3390/ijms20205172
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. (A) GO classification of the assembled differential expression genes (DEGs) of grass carp pituitary cells into molecular function, biological function, cellular component. (B) KEGG pathway enrichment analysis for DEGs in grass carp pituitary. Statistics of the top 10 enriched pathways for DEGs of up and down regulation. Up, up-regulated genes; down, down-regulated genes; count, the number of DEGs.
Up-regulated genes by epidermal growth factor (EGF) in grass carp pituitary cells.
| Gene | FC | Description | Molecular Function | |
|---|---|---|---|---|
|
| 1.81 | 1.39 × 10−3 | DEAH-box helicase 33 | ATP binding, helicase activity |
|
| 2.04 | 4.99 × 10−8 | Creatine kinase M-type | ATP binding, kinase activity |
|
| 1.74 | 8.70 × 10−4 | Deoxycytidine kinase | ATP binding, nucleoside kinase activity |
|
| 2.11 | 1.05 × 10−38 | Rho GTPase-activating protein 10 | Calcium ion binding |
|
| 1.7 | 3.82 × 10−11 | Calcium-activated potassium channel subunit alpha | Calcium-activated potassium channel activity |
|
| 1.85 | 5.09 × 10−14 | Sphingosine-1-phosphate phosphatase 1 | Catalytic activity |
|
| 1.9 | 1.39 × 10−5 | Cytochrome c oxidase subunit 6B1 | Cytochrome-c oxidase activity |
|
| 3.75 | 2.20 × 10−151 | Early growth response protein 1 | DNA binding,metal ion binding |
|
| 1.74 | 1.01 × 10−10 | Endothelin B receptor | Endothelin receptor activity |
|
| 1.7 | 7.60 × 10−16 | ETS translocation variant 5 | Equence-specific DNA binding |
|
| 2.93 | 9.81 × 10−15 | Fatty acid-binding protein, brain | Fatty acid binding,transporter activity |
|
| 3.53 | 6.37 × 10−7 | Cadherin-1 | G-protein alpha-subunit binding |
|
| 2.12 | 5.92 × 10−9 | Ras-related protein Rab-37 | GTP binding |
|
| 1.99 | 2.19 × 10−9 | Ras-related protein R-Ras2 | GTP binding |
|
| 1.93 | 8.35 × 10−11 | Rho GTPase-activating protein 10 | Gtpase activator activity |
|
| 1.75 | 9.95 × 10−28 | Ral guanine nucleotide dissociation stimulator | Guanyl-nucleotide exchange factor activity |
|
| 24.99 | 7.16 × 10−149 | Urotensin1 | Hormone activity |
|
| 1.83 | 2.80 × 10−49 | Somatolactin | Hormone activity |
|
| 1.86 | 1.09 × 10−51 | Prolactin | Hormone activity |
|
| 1.79 | 7.90 × 10−10 | Hyaluronan synthase 2 | Hyaluronan synthase activity |
|
| 1.7 | 3.56 × 10−2 | CDK5 regulatory subunit-associated protein 1-like 1 | Kdo transferase activity |
|
| 2.32 | 9.56 × 10−59 | High affinity cGMP-specific 3 | Metal ion binding |
|
| 1.79 | 2.06 × 10−19 | Polypeptide N-acetylgalactosaminyltransferase 12 | Metal ion binding, transferase activity |
|
| 289.6 | 0.00 | Collagenase 3 | Metalloendopeptidase activity |
|
| 2.09 | 2.62 × 10−6 | _ | Neurotrophin receptor activity |
|
| 1.86 | 9.31 × 10−32 | Cell adhesion molecule 4 | Protein binding |
|
| 1.97 | 2.60 × 10−27 | threonine-protein kinase 40 | Protein serine/threonine kinase activity |
|
| 1.82 | 6.61 × 10−18 | Dual specificity protein phosphatase 14 | Protein tyrosine phosphatase activity |
|
| 2.28 | 9.33 × 10−18 | Dual specificity protein phosphatase 2 | Protein tyrosine phosphatase activity |
|
| 2.46 | 4.73 × 10−16 | Dual specificity protein phosphatase 4 | Protein tyrosine phosphatase activity |
|
| 1.83 | 7.81 × 10−6 | Dual specificity protein phosphatase 5 | Protein tyrosine phosphatase activity |
|
| 2.08 | 7.58 × 10−31 | Dual specificity protein phosphatase 7 | Protein tyrosine phosphatase activity |
|
| 2.85 | 1.93 × 10−14 | Serine-proteinkinase OSR1 | Receptor signaling protein kinase activity |
|
| 5.22 | 4.15 × 10−47 | Corin, serine peptidase | Serine-type endopeptidase activity |
|
| 2.05 | 1.85 × 10−3 | Leukocyte elastase inhibitor | Serine-type endopeptidase inhibitor activity |
|
| 2.14 | 5.43 × 10−17 | Keratin, type II cytoskeletal 8 | Structural molecule activity |
|
| 1.7 | 1.02 × 10−4 | Complexin-3 | Syntaxin binding |
|
| 1.68 | 2.34 × 10−3 | Thiopurine S-methyltransferase | Thiopurine S-methyltransferase activity |
|
| 2.46 | 5.59 × 10−47 | Fos-related antigen 1 | Transcription factor activity |
|
| 2 | 1.12 × 10−6 | Brachyury protein homolog A | Transcription regulatory region DNA binding |
|
| 1.78 | 3.30 × 10−12 | Receptor-type tyrosine-protein phosphatase mu | Transmembrane receptor activity |
|
| 1.72 | 1.73 × 10−10 | Probable E3 ubiquitin-protein ligase RNF144A-A | Tubulin-glycine ligase activity |
|
| 1.68 | 3.04 × 10−13 | Myeloid differentiation primary response protein MyD88 | Tyrosine kinase activity |
|
| 1.94 | 6.54 × 10−10 | Vasopressin V2 receptor | Vasopressin receptor activity |
|
| 2.39 | 1.18 × 10−3 | Galactose-1-phosphate uridylyltransferase | Zinc ion binding |
|
| 1.74 | 1.44 × 10−2 | Zinc finger CCHC domain-containing protein 9 | Zinc ion binding, nucleic acid binding |
FC: fold change.
Down-regulated genes by EGF in grass carp pituitary cells.
| Gene | FC | Description | Molecular Function | |
|---|---|---|---|---|
|
| 0.55 | 1.69 × 10−5 | Very-long-chain enoyl-CoA reductase | Acting on the CH-CH group of donors |
|
| 0.49 | 1.5 × 10−20 | Adenylate cyclase type 6 | Adenylate cyclase activity |
|
| 0.50 | 8.4×10−15 | Nuclear receptor-interacting protein 2 | Aspartic-type endopeptidase activity |
|
| 0.36 | 7.2 × 10−35 | Ephrin type-A receptor 3 | ATP binding |
|
| 0.52 | 1.1 × 10−21 | Heat shock cognate 70 | ATP binding |
|
| 0.55 | 6.03 × 10−8 | Heat shock protein70 | ATP binding |
|
| 0.38 | 2.2 × 10−40 | Cadherin-11 | Calcium ion binding |
|
| 0.51 | 0.000023 | Calcineurin B homologous protein 1 | Calcium ion binding |
|
| 0.50 | 6.3 × 10−9 | Transmembrane prolyl 4-hydroxylase | Calcium ion binding |
|
| 0.53 | 2.3 × 10−11 | Carbonic anhydrase 2 | Carbonate dehydratase activity, zinc ion binding |
|
| 0.51 | 4.1 × 10−8 | _ | Delayed rectifier potassium channel activity |
|
| 0.58 | 1.84 × 10−13 | RING1 and YY1-binding protein A | DNA binding |
|
| 0.57 | 1.5 × 10−6 | Eukaryotic translation initiation factor 2-alpha kinase 2 | Double-stranded RNA adenosine deaminase activity |
|
| 0.56 | 5.83 × 10−23 | Thrombospondin-1 | Extracellular matrix binding |
|
| 0.50 | 7.1 × 10−8 | Neurotensin receptor type 1 | G-protein coupled neurotensin receptor activity |
|
| 0.57 | 0.00158 | Ras-related protein Rab-39B | GTP binding |
|
| 0.44 | 6.6 × 10−20 | GTP-binding protein REM 2 | GTP binding |
|
| 0.56 | 9.36 × 10−7 | Rho-related GTP-binding protein RhoE | GTP binding |
|
| 0.57 | 5.4 × 10−8 | Probable ATP-dependent RNA helicase DDX58 | Helicase activity, nucleic acid binding |
|
| 0.29 | 6.2 × 10−36 | Cytochrome P450 4V2 | Heme binding, iron ion binding |
|
| 0.42 | 2 × 10−7 | p21-Rac3; Flags: Precursor | Hydrolase activity |
|
| 0.31 | 2.7×10−55 | Lipoprotein lipase | Lipoprotein lipase activity |
|
| 0.46 | 0.000016 | Polypeptide GalNAc transferase 13 | Metal ion binding |
|
| 0.54 | 1.1 × 10−7 | DNA J homolog subfamily A member 4 | Metal ion binding, heat shock protein binding |
|
| 0.54 | 2.17 × 10−10 | General transcription factor IIIA | Metal ion binding,nucleic acid binding |
|
| 0.57 | 2.26 × 10−6 | Poly (ADP-ribose) polymerase family, member 12b | Metal ion binding |
|
| 0.58 | 4.74 × 10−7 | TRAF3-interacting protein 1 | Microtubule binding |
|
| 0.58 | 1.43 × 10−13 | Tissue inhibitor of metalloproteinase 3 | _ |
|
| 0.52 | 1.5 × 10−10 | Actin, alpha cardiac muscle 1 | Myosin binding |
|
| 0.54 | 0.00001 | DEAD box protein 58 | Nucleic acid binding |
|
| 0.53 | 4.2 × 10−17 | NK-tumor recognition protein | Peptidyl-prolyl cis-trans isomerase activity |
|
| 0.53 | 2.8 × 10−10 | CD53 molecule | Protein binding |
|
| 0.52 | 1.8 × 10−13 | Protein tyrosine kinase 7 | Protein tyrosine kinase activity |
|
| 0.47 | 1.6 × 10−11 | Siah E3 ubiquitin protein ligase 1 | Protein-glycine ligase activity |
|
| 0.41 | 1.9 × 10−34 | Integrin beta-2 | Receptor activity |
|
| 0.53 | 7.4 × 10−12 | Notch 1 extracellular truncation | Receptor activity, calcium ion binding |
|
| 0.36 | 3.3 × 10−46 | Neuropilin-2 | Semaphorin receptor activity |
|
| 0.56 | 0.00635 | Nuclear factor NF-kappa-B p105 subunit | DNA binding transcription factor activity |
|
| 0.57 | 0.003 | GalNAc alpha-2,6-sialyltransferase III | Sialyltransferase activity |
|
| 0.46 | 6 × 10−43 | Excitatory amino acid transporter 1 | Sodium:dicarboxylate symporter activity |
|
| 0.47 | 4.9×10−17 | UDP-glucuronosyltransferase 1-1 | Transferase activity |
|
| 0.55 | 4.51 × 10−7 | Beta-1,4-galactosyltransferase 3 | Transferase activity, transferring glycosyl groups |
|
| 0.52 | 7.5 × 10−12 | NT-3 growth factors receptor | Transmembrane receptor protein tyrosine kinase activity |
|
| 0.36 | 7.2 × 10−63 | Monocarboxylate transporter 2 | Transmembrane transporter activity |
|
| 0.43 | 6.1 × 10−17 | Synaptic vesicle glycoprotein 2B | Transmembrane transporter activity |
|
| 0.33 | 3.2 × 10−30 | Ligand of Numb protein X 4 | Ubiquitin-protein transferase activity |
|
| 0.43 | 9.4 × 10−30 | Secreted frizzled-related protein 2 | Wnt-protein binding |
|
| 0.54 | 0.002 | Archaemetzincin-2 | Zinc ion binding |
Figure 2DEGs were enriched in the biological process of cell migration, cell differentiation, signal transduction, metabolic process, phosphorylation, and regulation of transcription in grass carp pituitary cells cultured by EGF treatment. Red indicates that the gene is increased, green indicates the gene is decreased in abundance relative to the control group and grey in the caption indicates the categories of biological process.
Figure 3Synergistic effects of EGF on UTS1 mRNA expression and receptor specificity and post-receptor signal pathway of EGF (0.5 μM)-induced UTS1 mRNA expression in grass carp pituitary cells. (A) Time course of EGF (0.5 μM) treatment on UTS1 mRNA expression. (B) Effect of EGF concentration (0.05–500 nM)-induced on UTS1 mRNA expression in grass carp pituitary cells. (C–E) Effects of ErbB1 antagonist AG1478, ErbB2 antagonist AG879, and IGF receptor antagonist AG1024 on EGF-induced UTS1 mRNA expression, respectively. (F–H) The effects of EGF (0.5 μM) induced UTS1 mRNA transcription with the MEK inhibitor U0126 (10 μM), ERK1/2 inhibitor LY3214996 (10 μM), and p38MAPK inhibitor SB203580, respectively. (I–K) Co-treatment with the PI3K inhibitor Wortmannin (10 μM), AKT inhibitor MK2206 (10 μM), and mTOR inhibitor Rapamycin (10 μM) on EGF (0.5 μm)-induced UTS1 mRNA expression for 24 h, respectively. After drug treatment, total RNA was isolated and used for real-time PCR of UTS1 mRNA expression. The differences between groups were considered as significant at p < 0.05 (“*”) or highly significant at p < 0.01 (“**”). The groups denoted by different letters represent a significant difference at p < 0.05.
Figure 4EGF induced EGR1 mRNA expression in grass carp pituitary cells, including receptor specificity and signal transduction pathways. (A) In the time course experiment, pituitary cells were treated with EGF (0.5 μM). (B) In the dose experiment, pituitary cells were cultured with EGF (0.05–500 nM). (C–E) Receptor specificity of EGF (0.5 µM)-induced EGR1 mRNA expression; effects of ErbB1 antagonist AG1478 (10 µM), ErbB2 antagonist AG879 (10 µM), and IGF receptor antagonist AG1024 (10 µM) on EGR1 mRNA expression for 24 h, respectively. (F–H) Signal transduction of EGR1 mRNA expression induced by EGF (0.5 μM) in grass carp pituitary cells. The effects of UTS1 mRNA transcription induced by EGF (0.5 μM) with EGF (0.5 μM) in the presence or absence of the MEK inhibitor U0126 (10 μM), ERK1/2 inhibitor LY3214996 (10 μM), or p38MAPK inhibitor SB203580 (10 μM), respectively. (I–K) The effects of EGF (0.5 μM) induced EGR1 mRNA expression with the PI3K inhibitor Wortmannin (10 μM), AKT inhibitor MK2206 (10 μM), or mTOR inhibitor Rapamycin (10 μM) by EGF (0.5 μM)-induced EGR1 mRNA expression for 24 h, respectively. After drug treatment, total RNA was isolated and used for real-time PCR of UTS1 mRNA expression. The differences between groups were considered as highly significant at p < 0.01 (“**”). The groups denoted by different letters represent a significant difference at p < 0.05.
Figure 5EGF induced MMP13 mRNA expression and receptor specificity and signal transduction mechanism in grass carp pituitary cells. (A) Pituitary cells were treated with EGF (0.5 μM) in a time dependent manner. (B) dose-dependent manner of EGF (0.05–500 nM) induced MMP13 mRNA expression, respectively. (C–E) Effects of ErbB1 antagonist AG1478 (10 µM), ErbB2 antagonist AG879 (10 µM), and IGF receptor antagonist AG1024 (10 µM) on MMP13 mRNA expression for 24 h, respectively. (F–H) Signal transduction of EGF-induced MMP13 mRNA expression in grass carp pituitary cells. Co-treatment of 24 h with the MEK blocker U0126 (10 μM), ERK1/2 inhibitor LY3214996 (10 μM), or p38MAPK inhibitor SB203580(10 μM) induced MMP13 mRNA expression was examined in grass carp pituitary cells, respectively. (I–K) Co-treatment of 24 h with the PI3K inhibitor Wortmannin (10 μM), AKT inhibitor MK2206 (10 μM), and mTOR inhibitor Rapamycin (10 μM) induced MMP13 mRNA expression was examined, respectively. After drug treatment, total RNA was isolated for real-time PCR of MMP13 mRNA expression. The differences between groups were considered as significant at p < 0.05 (“*”) or highly significant at p < 0.01 (“**”). The groups denoted by different letters represent a significant difference at p < 0.05.
Figure 6EGF induced TIMP3 mRNA expression and receptor specificity in grass carp pituitary. (A) Time course of EGF (0.5 μM) treatment on TIMP3 mRNA expression. (B) Effect of EGF concentration (0.05–500 nM)-induced on TIMP3 mRNA expression in grass carp pituitary cells. (C–E) Effects of ErbB1 antagonist AG1478 (10 µM), ErbB2 antagonist AG879 (10 µM), and IGF receptor antagonist AG1024 (10 µM) on TIMP3 mRNA expression for 24 h, respectively. After drug treatment, total RNA was isolated for real-time PCR of MMP13 mRNA expression. In the data present (mean ± SEM), the differences between groups were considered as significant at p < 0.05 (“*”) or highly significant at p < 0.01 (“**”). The groups denoted by different letters represent a significant difference at p < 0.05.
Figure 7The functional role of in EGF-induced UTS1 and EGR1 in grass carp pituitary. (A) Effect of the inhibitor of MMPs BB94 (10 µM) on UTS1 mRNA expression. (B) Effect of the inhibitor of MMPs BB94 (10 µM) on EGR1 mRNA expression. After drug treatment, total RNA was isolated for real-time PCR of UTS1 and EGR1 mRNA expression. In the data present (mean ± SEM), the differences between groups were considered as significant at p < 0.05 with different letters.
Figure 8Working modal of EGF-induced UTS1, EGR1, MMP13, and TIMP3 regulation in grass carp pituitary. EGF induced UTS1 and EGR1 mRNA expression were mediated by the PI3K/AKT/mTOR and MEK1/2/ERK1/2 pathways coupled with both ErbB1 and ErbB2. EGF-induced MMP13 mRNA expression was only through the MEK1/2/ERK1/2 pathway coupled with ErbB1 and inhibited TIMP3 mRNA expression via ErbB1. EGF-induced MMP13 might be involved in the up-regulation of UTS1 and EGR1 mRNA expression by EGF in grass carp pituitary cells. The solid arrows indicated that the actions were verified by our study, the dotted arrows indicated that the actions were verified basing on the references. And the dotted “T” represented the inhibited action basing on the references.